NovoCure Ltd 8-K/A

What Happened

• NovoCure Ltd filed an amendment to a previously reported Form 8-K (Item 5.02) to provide the previously-undetermined compensation details for Frank Leonard in connection with his appointment as Chief Executive Officer effective December 1, 2025.
• The amendment also includes an employment agreement between Frank Leonard and Novocure GmbH effective January 1, 2026 (filed as Exhibit 10.1) and was filed under Item 9.01 (financial statements and exhibits). The report was signed by CFO Christoph Brackmann (dated February 25, 2026) and filed on April 24, 2026.

Key Details

• Item reported: 5.02 — Departure/election of officers; this amendment adds compensation details for the CEO appointment.
• CEO effective date: December 1, 2025 (Frank Leonard).
• Employment agreement effective date: January 1, 2026 (Exhibit 10.1 attached).
• Amendment note: The filing states it does not modify or update other disclosures from the initial Form 8-K.

Why It Matters

• Leadership and compensation are material governance items: investors should be aware that NovoCure has finalized and disclosed the pay and contractual terms for its new CEO, which can affect executive incentives and company expenses.
• The attached employment agreement lets investors review specific contract terms (effective dates, potential compensation structure, and other provisions) rather than relying on summary language.
• Retail investors who track corporate governance, executive turnover, or potential changes in company strategy may want to read Exhibit 10.1 in the 8-K amendment for full details.